[Effects of Peri-immunosupressive Therapy Period Infection on Hematologic Response and Survival of Severe Aplastic Anemia]

Overview

Journal Zhonghua Xue Ye Xue Za Zhi

Specialty Hematology

Date 2015 Oct 15

PMID 26462637

Authors

Lei Ye

Liping Jing

Wenrui Yang

Kang Zhou

Guangxin Peng

Yang Li

Yuan Li

Jianping Li

Lin Song

Zhijie Wu

Fengkui Zhang

Li Zhang

Affiliations

Soon will be listed here.

Abstract

Objective: To explore the effects of peri-immunosuppressive treatment（IST）infection on outcomes of severe and very severe aplastic anemia（SAA/VSAA）patients.

Methods: Medical record and follow-up data of 105 SAA/VSAA who underwent first-line IST were retrospectively analyzed to find out the characters of infections（1 month before to 3 months after IST）, and its effects on hematologic response and survival.

Results: Of 105 patients, a total of 270 febrile episodes were recorded in 97 patients（92.4%）during their peri- IST periods, with the median infections of 2（1-7）episodes in each patient with the median febrile duration of 7（1-47）days. Respiratory system（35.1%）was the primary anatomic site of infection. Bacteria（88.2%）were common causes of total 169 pathogenic bacteria in 96 clear pathogenic bacteria episodes. And patients who got infection 1 month before IST had much lower 6- month hematologic response rate than their counterpart ones（50.8% vs 80.0%, P=0.004）. Multiple febrile episodes （ ≥3 times） and the total febrile duration ≥4 days showed the best sensitivity and specificity according to the ROC curve analysis. The 5-year overall survival of the 105 patients was 76%. The 5- year OS of patients with multiple febrile episodes （ ≥3 times） were much lower than their counterpart ones［（59.6±7.2）% vs（89.5±4.0）%］（P＜0.01）. The 5-year OS of the total febrile duration ≥4 days was much lower than their counterpart ones［（63.4±5.8）% vs 100.0%］（P＜0.01）.

Conclusion: Infections 1 month before IST were associated with hematologic response. Multiple febrile episodes（≥3 times） and infections with the febrile duration ≥4 days presented inferior hematologic response and survival.

References

Marsh J, Ball S, Cavenagh J, Darbyshire P, Dokal I, Gordon-Smith E . Guidelines for the diagnosis and management of aplastic anaemia. Br J Haematol. 2009; 147(1):43-70. DOI: 10.1111/j.1365-2141.2009.07842.x. View

Sakamoto T, Obara N, Kurita N, Sakata-Yanagimoto M, Nishikii H, Yokoyama Y . Effectiveness and safety of rabbit anti-thymocyte globulin in Japanese patients with aplastic anemia. Int J Hematol. 2013; 98(3):319-22. DOI: 10.1007/s12185-013-1418-5. View

Walsh T, Pappas P, Winston D, Lazarus H, Petersen F, Raffalli J . Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med. 2002; 346(4):225-34. DOI: 10.1056/NEJM200201243460403. View

Baumelou E, Guiguet M, Mary J . Epidemiology of aplastic anemia in France: a case-control study. I. Medical history and medication use. The French Cooperative Group for Epidemiological Study of Aplastic Anemia. Blood. 1993; 81(6):1471-8. View

Valdez J, Scheinberg P, Nunez O, Wu C, Young N, Walsh T . Decreased infection-related mortality and improved survival in severe aplastic anemia in the past two decades. Clin Infect Dis. 2011; 52(6):726-35. PMC: 3106262. DOI: 10.1093/cid/ciq245. View

Scheinberg P, Wu C, Nunez O, Scheinberg P, Boss C, Sloand E . Treatment of severe aplastic anemia with a combination of horse antithymocyte globulin and cyclosporine, with or without sirolimus: a prospective randomized study. Haematologica. 2009; 94(3):348-54. PMC: 2649367. DOI: 10.3324/haematol.13829. View

Tichelli A, Schrezenmeier H, Socie G, Marsh J, Bacigalupo A, Duhrsen U . A randomized controlled study in patients with newly diagnosed severe aplastic anemia receiving antithymocyte globulin (ATG), cyclosporine, with or without G-CSF: a study of the SAA Working Party of the European Group for Blood and Marrow.... Blood. 2011; 117(17):4434-41. DOI: 10.1182/blood-2010-08-304071. View

. Incidence of aplastic anemia: the relevance of diagnostic criteria. By the International Agranulocytosis and Aplastic Anemia Study. Blood. 1987; 70(6):1718-21. View

Torres H, Bodey G, Rolston K, Kantarjian H, Raad I, Kontoyiannis D . Infections in patients with aplastic anemia: experience at a tertiary care cancer center. Cancer. 2003; 98(1):86-93. DOI: 10.1002/cncr.11478. View

10.

Risitano A, Selleri C, Serio B, Torelli G, Kulagin A, Maury S . Alemtuzumab is safe and effective as immunosuppressive treatment for aplastic anaemia and single-lineage marrow failure: a pilot study and a survey from the EBMT WPSAA. Br J Haematol. 2009; 148(5):791-6. DOI: 10.1111/j.1365-2141.2009.08027.x. View

11.

Brodsky R, Chen A, Dorr D, Fuchs E, Huff C, Luznik L . High-dose cyclophosphamide for severe aplastic anemia: long-term follow-up. Blood. 2009; 115(11):2136-41. PMC: 2844020. DOI: 10.1182/blood-2009-06-225375. View

12.

Freifeld A, Bow E, Sepkowitz K, Boeckh M, Ito J, Mullen C . Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2011; 52(4):427-31. DOI: 10.1093/cid/ciq147. View

13.

Hughes W, Armstrong D, Bodey G, Brown A, Edwards J, Feld R . 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America. Clin Infect Dis. 1997; 25(3):551-73. DOI: 10.1086/513764. View

14.

Valdez J, Scheinberg P, Young N, Walsh T . Infections in patients with aplastic anemia. Semin Hematol. 2009; 46(3):269-76. DOI: 10.1053/j.seminhematol.2009.03.008. View

15.

Rosenfeld S, Follmann D, Nunez O, Young N . Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome. JAMA. 2003; 289(9):1130-5. DOI: 10.1001/jama.289.9.1130. View

16.

Passweg J, Marsh J . Aplastic anemia: first-line treatment by immunosuppression and sibling marrow transplantation. Hematology Am Soc Hematol Educ Program. 2011; 2010:36-42. DOI: 10.1182/asheducation-2010.1.36. View

17.

Bacigalupo A, Hows J, Gluckman E, Nissen C, Marsh J, Van Lint M . Bone marrow transplantation (BMT) versus immunosuppression for the treatment of severe aplastic anaemia (SAA): a report of the EBMT SAA working party. Br J Haematol. 1988; 70(2):177-82. DOI: 10.1111/j.1365-2141.1988.tb02460.x. View